Figure 2From: Tetrabenazine as anti-chorea therapy in Huntington Disease: an open-label continuation study. Huntington Study Group/TETRA-HD Investigators Dosage distribution by percent of subjects at weeks 24, 48 and 80 for the 44 subjects who continued to take tetrabenazine through week 80.Back to article page